"A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantation"
2022-06-27
عنوان الدراسة
"A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantation"
داعم الدراسة
Novartis
دواء الدراسة
ruxolitinib
رقم بروتوكول الدراسة
CINC424G12201
حالة الدراسة
Completed
موقع الدراسة
KFSH&RC-R
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。